Your browser is no longer supported. Please, upgrade your browser.
Settings
CBAY Cymabay Therapeutics, Inc. daily Stock Chart
CBAY [NASD]
Cymabay Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.06 Insider Own0.30% Shs Outstand42.78M Perf Week7.39%
Market Cap323.42M Forward P/E- EPS next Y-0.69 Insider Trans18.46% Shs Float42.78M Perf Month19.43%
Income-27.10M PEG- EPS next Q-0.19 Inst Own28.10% Short Float3.06% Perf Quarter47.37%
Sales4.80M P/S67.38 EPS this Y-38.40% Inst Trans6.20% Short Ratio1.13 Perf Half Y98.43%
Book/sh0.07 P/B108.00 EPS next Y14.80% ROA-122.90% Target Price13.43 Perf Year283.76%
Cash/sh0.39 P/C19.37 EPS next 5Y- ROE-425.00% 52W Range1.15 - 8.29 Perf YTD336.99%
Dividend- P/FCF- EPS past 5Y5.30% ROI- 52W High-8.82% Beta2.01
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin- 52W Low557.39% ATR0.40
Employees21 Current Ratio1.50 Sales Q/Q- Oper. Margin- RSI (14)63.47 Volatility5.90% 5.47%
OptionableYes Debt/Eq3.57 EPS Q/Q-4.10% Profit Margin- Rel Volume0.68 Prev Close7.69
ShortableYes LT Debt/Eq2.19 EarningsAug 10 AMC Payout- Avg Volume1.16M Price7.56
Recom1.70 SMA2015.02% SMA5012.24% SMA20077.68% Volume781,372 Change-1.69%
Aug-23-17Initiated Leerink Partners Outperform $12
Aug-18-17Initiated SunTrust Buy $15
Jul-20-17Reiterated Oppenheimer Outperform $8 → $15
Jun-23-17Initiated Oppenheimer Outperform $8
Jan-30-17Upgrade H.C. Wainwright Neutral → Buy $2.50 → $6
Jan-04-17Reiterated H.C. Wainwright Neutral $1.50 → $2.50
Jun-01-16Downgrade H.C. Wainwright Buy → Neutral $2.25
Sep-08-15Initiated H.C. Wainwright Buy $12
Jul-21-15Initiated Piper Jaffray Overweight $4
May-08-15Reiterated Stifel Buy $15 → $9
Jan-20-15Reiterated Stifel Buy $10 → $15
Sep-18-17 08:00AM  CymaBay Therapeutics to Present at Two Investor Conferences GlobeNewswire
Sep-12-17 12:50PM  Intercept Pharmaceuticals Inc (ICPT) Stock Dives on Drug Warning InvestorPlace +7.34%
Sep-11-17 08:00AM  CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis GlobeNewswire +5.38%
Aug-15-17 08:30AM  CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology GlobeNewswire
Aug-10-17 04:01PM  CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Aug-09-17 08:33AM  Why CymaBay Therapeutics (CBAY) Might Surprise This Earnings Season Zacks
Aug-07-17 08:00AM  CymaBay to Report Second Quarter 2017 Financial Results on Thursday, August 10 GlobeNewswire
Jul-24-17 04:05PM  CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-20-17 08:15AM  Cymabay Therapeutics (CBAY) Catches Eye: Stock Gains 6.2% Zacks
Jul-19-17 11:34AM  Oppenheimer Bullish on Bank of America Corp (BAC), CymaBay Therapeutics Inc (CBAY) and TherapeuticsMD Inc (TXMD); Heres Why SmarterAnalyst +6.20%
08:30AM  CymaBay Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jul-18-17 08:10AM  Today's Research Reports on Stocks to Watch: Editas Medicine and Cymabay Therapeutics Accesswire +16.05%
Jul-17-17 04:15PM  CymaBay Announces Proposed Public Offering of Common Stock GlobeNewswire +5.84%
10:16AM  H.C. Wainwright Boosts Price Target on CymaBay Therapeutics Inc (CBAY) SmarterAnalyst
07:30AM  CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis GlobeNewswire
Jul-13-17 08:36AM  Implied Volatility Surging for Cymabay Therapeutics (CBAY) Stock Options Zacks +6.62%
Jul-03-17 09:28AM  New Analyst Coverage Make These 5 Stocks Worth a Bet Zacks
Jun-30-17 04:09PM  Penny Stocks to Watch for July 2017 Investopedia
Jun-26-17 08:00AM  CymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance GlobeNewswire
May-11-17 04:01PM  CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
03:00PM  Investor Network: CymaBay Therapeutics, Inc. to Host Earnings Call Accesswire
May-04-17 08:00AM  CymaBay to Report First Quarter 2017 Financial Results on Thursday, May 11 GlobeNewswire
Apr-13-17 08:00AM  CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017 GlobeNewswire
Mar-30-17 08:00AM  CymaBay Therapeutics to Present at Two Investor Conferences in April GlobeNewswire
Mar-29-17 01:04PM  CYMABAY THERAPEUTICS, INC. Financials
08:02AM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
08:00AM  CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D. GlobeNewswire
Mar-23-17 04:01PM  CymaBay Reports Fourth Quarter and Year End 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 CymaBay Therapeutics Inc Earnings Release - Time Not Supplied
Mar-16-17 04:48PM  CymaBay to Report Fourth Quarter And Year End 2016 Financial Results on Thursday, March 23 GlobeNewswire
Mar-15-17 10:37AM  Will Cymabay Therapeutics (CBAY) Continue to Surge Higher? Zacks
Mar-09-17 08:00AM  CymaBay Therapeutics to Present at Two Investor Conferences in March GlobeNewswire +20.29%
Mar-08-17 09:30AM  Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro Zacks
Mar-07-17 02:41PM  Explosive Stocks Under $10 Zacks
Feb-22-17 09:30AM  The Zacks Analyst Blog Highlights: Cymabay Therapeutics, Attunity, Lumentum Holdings, Datawatch and Arconic Zacks
Feb-21-17 05:34PM  5 Top Performers of Trump's First 30 Days in Office Zacks
Feb-14-17 10:28AM  Can The Uptrend Continue for Cymabay Therapeutics (CBAY)?
Feb-13-17 09:40AM  Cerner's EHR Platform to Enhance Health Care at San Juan NGO
Feb-10-17 08:49AM  5 Breakout Stocks for Superior Returns +5.38%
Feb-09-17 08:30AM  Cymabay Therapeutics (CBAY) Rises: Stock Moves 9.2% Higher
Feb-07-17 08:00AM  CymaBay Therapeutics to Present at the 2017 BIO CEO & Investor Conference GlobeNewswire
Feb-03-17 04:07PM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-02-17 09:15AM  CymaBay Announces Pricing of Public Offering of Common Stock GlobeNewswire
Feb-01-17 04:01PM  CymaBay Announces Proposed Public Offering of Common Stock GlobeNewswire +11.83%
Jan-30-17 07:02AM  CymaBay Therapeutics upgraded by H.C. Wainwright +10.18%
Jan-24-17 06:15AM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-05-17 08:00AM  CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate GlobeNewswire
06:04AM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Jan-04-17 12:15PM  Wednesdays Top 5 Biopharma Movers +21.05%
11:00AM  Taking A Look At CymaBay Therapeutics Inc (CBAY)s Big Deal at Insider Monkey
08:10AM  Heres Why Apple, Tesla, and Three Other Stocks Are Trending at Insider Monkey
Jan-03-17 04:01PM  CymaBay Announces Exclusive Licensing Agreement with Kowa Pharmaceuticals America, Inc. for the Development and Commercialization of Arhalofenate in the United States GlobeNewswire +9.83%
Dec-16-16 07:54PM  Pain Therapeutics, Inc. (PTIE): How Does It Compare Against Its Peers? at Insider Monkey
Dec-08-16 08:01AM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -13.71%
08:00AM  CymaBay Announces the Appointments of Robert Booth, Ph.D. and Caroline Loewy to Its Board of Directors GlobeNewswire
Dec-07-16 08:00AM  CymaBay Therapeutics Announces the Initiation of its Next Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis GlobeNewswire
Dec-06-16 04:10PM  Anthera Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of blisibimod for IgA Nephropathy GlobeNewswire
08:00AM  CymaBay Therapeutics Announces that the Recommended International Nonproprietary Name for MBX-8025 is Seladelpar GlobeNewswire
Nov-28-16 08:00AM  CymaBay Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-10-16 04:01PM  CymaBay to Host Key Opinion Leader Meeting on Primary Biliary Cholangitis in New York City GlobeNewswire +5.52%
08:00AM  CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 for the Treatment of Primary Biliary Cholangitis GlobeNewswire
Nov-09-16 04:05PM  CYMABAY THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report +13.28%
04:01PM  CymaBay Reports Third Quarter 2016 Financial Results GlobeNewswire
08:00AM  CymaBay Therapeutics Announces a Newly Issued U.S. Patent for the Use of MBX-8025 as a Treatment for Primary Biliary Cholangitis (PBC) GlobeNewswire
Nov-02-16 08:00AM  CymaBay to Announce Third Quarter 2016 Financial Results on Wednesday, November 9 GlobeNewswire
Oct-20-16 02:41PM  CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting GlobeNewswire -5.64%
08:00AM  CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines (PRIME) Designation for the Treatment of Primary Biliary Cholangitis GlobeNewswire
Oct-11-16 08:00AM  CymaBay Therapeutics Announces a Newly Issued U.S. Patent for MBX-8025 for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) GlobeNewswire
Oct-07-16 08:32AM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -6.11%
Oct-06-16 08:00AM  CymaBay Therapeutics Announces an Oral Presentation Describing the Efficacy of MBX-8025 in a Preclincal Model of NASH at the AASLD 2016 Liver Meeting GlobeNewswire
Oct-05-16 08:00AM  CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis GlobeNewswire -6.70%
Sep-08-16 08:00AM  CymaBay Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference GlobeNewswire
Aug-09-16 04:06PM  CYMABAY THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
04:01PM  CymaBay Reports Second Quarter 2016 Financial Results GlobeNewswire
Aug-02-16 08:00AM  CymaBay to Announce Second Quarter 2016 Financial Results on Tuesday, August 9 GlobeNewswire
Jul-07-16 08:00AM  CymaBay Announces Participation at Cantor Fitzgerald Healthcare Conference on July 12th in New York GlobeNewswire
Jun-06-16 04:33PM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-31-16 07:00AM  CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC) GlobeNewswire
May-24-16 08:06AM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure
May-19-16 08:00AM  CymaBay Therapeutics to Present at UBS Global Healthcare Conference GlobeNewswire
May-11-16 04:05PM  CYMABAY THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -5.51%
04:05PM  CymaBay Reports First Quarter 2016 Financial Results GlobeNewswire
May-02-16 08:00AM  CymaBay to Announce First Quarter 2016 Financial Results on Wednesday, May 11 GlobeNewswire
Apr-25-16 08:31AM  CymaBay Therapeutics Inc. (NASDAQ: CBAY) Analyst Coverage Initiated Accesswire +6.75%
Apr-21-16 11:57AM  Corporate Insiders at Alcoa Inc. (AA) and Two Other Battered Companies Keep Buying Shares at Insider Monkey
Apr-07-16 02:13PM  Penny Stocks To Watch: Thursday's List of Trending Small Cap Stocks April 7th Accesswire +29.50%
07:27AM  Actuant Corporation (ATU) and 2 Other Battered Companies Receive a Vote of Confidence from Insiders at Insider Monkey
Mar-30-16 04:26PM  Edited Transcript of CBAY earnings conference call or presentation 29-Mar-16 8:30pm GMT
Mar-29-16 04:05PM  CYMABAY THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:05PM  CymaBay Reports Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
Mar-28-16 04:04PM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers +5.11%
04:01PM  CymaBay Announces the Appointment of Paul F. Truex and Robert J. Weiland to its Board of Directors GlobeNewswire
08:00AM  CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology GlobeNewswire
Mar-24-16 09:58AM  Biotech Stock Mailbag: How to Spot Red Flags in Clinical Trial Data at TheStreet
Mar-22-16 08:03AM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
08:00AM  CymaBay Announces the Appointment of Dr. Evan Stein, M.D., Ph.D., to its Board of Directors GlobeNewswire
Mar-21-16 08:00AM  CymaBay to Announce Fourth Quarter and Year-End 2015 Financial Results on Tuesday, March 29 GlobeNewswire +8.46%
Mar-17-16 04:01PM  CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia GlobeNewswire +10.39%
Mar-10-16 06:00AM  5 Stocks Under $10 Set to Soar Higher at TheStreet -6.05%
Mar-03-16 08:00AM  CymaBay Therapeutics to Present at Two Upcoming Investor Conferences in March GlobeNewswire
CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. It engages in developing seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes. CymaBay Therapeutics Inc. has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products containing halofenate, its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics Inc. was incorporated in 1988 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wills Robert JamesDirectorAug 01Buy6.845,00034,22130,000Aug 02 08:21 AM
McWherter CharlesSVP & Chief Scientific OfficerJul 20Buy7.435,00037,13710,000Jul 24 06:19 AM
Shah SujalInterim President & CEOJul 20Buy7.3410,00073,40185,000Jul 24 06:15 AM